Fecal microbiota transplantation broadening its application beyond intestinal disorders.
Xu, Meng-Que, Cao, Hai-Long, Wang, Wei-Qiang et al. · World journal of gastroenterology · 2015 · DOI
Quick Summary
This review explores how fecal microbiota transplantation (FMT)—transferring healthy gut bacteria from donors to patients—might help treat conditions beyond intestinal diseases, including chronic fatigue syndrome. The authors found that FMT has shown promise in improving insulin sensitivity in metabolic disease and has produced favorable results in case reports of patients with Parkinson's disease, multiple sclerosis, and chronic fatigue syndrome, suggesting that gut bacteria imbalance may contribute to these conditions.
Why It Matters
For ME/CFS patients and researchers, this review is significant because it identifies dysbiosis as a potential therapeutic target and presents a case report suggesting FMT may benefit chronic fatigue syndrome. Understanding the role of gut microbiota in ME/CFS could open new treatment avenues and legitimize microbiota-directed interventions as an area for rigorous clinical investigation.
Observed Findings
Case reports documented favorable outcomes of FMT in chronic fatigue syndrome patients.
A randomized controlled trial of metabolic syndrome patients receiving lean donor FMT showed increased insulin sensitivity compared to autologous FMT controls.
Lean donor FMT was associated with increased levels of butyrate-producing intestinal microbiota.
FMT has demonstrated effectiveness in established intestinal disorders and shows promise in neuropsychiatric, autoimmune, and allergic conditions.
Favorable outcomes reported in case series of Parkinson's disease, multiple sclerosis, and myoclonus dystonia.
Inferred Conclusions
Intestinal dysbiosis is implicated in the pathogenesis of multiple extra-intestinal disorders including chronic fatigue syndrome.
FMT is a promising microbiota-targeted therapeutic approach for conditions associated with dysbiosis beyond traditional intestinal indications.
Lean donor microbiota transfer produces metabolic benefits, suggesting donor selection may be clinically important.
Further investigation of FMT in extra-intestinal conditions is warranted.
Remaining Questions
What specific bacterial taxa or functional capacities are deficient in ME/CFS patients and how do they relate to symptom mechanisms?
What This Study Does Not Prove
This review does not prove that FMT is effective for ME/CFS, as the evidence consists only of case reports without controls, blinding, or standardized outcome measures. The study does not establish causality between dysbiosis and ME/CFS symptoms, nor does it demonstrate that FMT outcomes in other conditions (metabolic syndrome, Parkinson's disease) will translate to ME/CFS populations. Cross-disease comparisons may not reflect disease-specific microbiota-symptom relationships.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →